Integrative Analysis of Human Glioblastoma Multiforme

Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · Dec 23, 2016

Keywords

ClinConnect Summary

This clinical trial, titled "Integrative Analysis of Human Glioblastoma Multiforme," is studying a type of brain cancer known as glioblastoma (GBM). The goal is to better understand how this cancer behaves and to identify potential new ways to treat it. The trial is currently recruiting participants, and it's open to individuals aged 65 to 75 years who have been diagnosed with GBM. To qualify, participants should have a good level of health without major organ problems and should not have undergone any previous chemotherapy for cancer.

If you or a loved one decides to participate, you'll be part of important research that could lead to advancements in GBM treatment. Participants will undergo assessments to ensure they meet the health criteria and will be monitored throughout the trial. It's important to note that individuals over 75, those with serious health issues, or those who have previously received chemotherapy for cancer are not eligible to join. This trial offers a chance to contribute to our understanding of GBM and potentially help improve outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≤ 75 years with histologically proven GBM
• • No severe major organ dysfunction
• • World Health Organization (WHO) performance status of 0 or 1
• • No prior cancer chemotherapy
• Exclusion Criteria:
• • Age ≥ 76
• • Severe major organ dysfunction
• • WHO performance status of \>1
• • Prior cancer chemotherapy